Significant funding rounds are powering the next wave of innovation this week in MedTech – from brain-computer interfaces and muscle-computer tech to structural heart devices and continuous biosensing. Capital is enabling U.S. and global expansion, clinical milestones, and the commercialization of high-impact medical technologies.
Science Corporation closes a $230M Series C to support BCI tech
Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT and Quiet Capital, among others, participated in the round. It brings the company’s total capital raised to approximately $490 million since its founding in 2021.
The company plans to use the funds to accelerate the commercialization of its brain-computer interface (BCI) technology and to support the advancement of its Biohybrid neural interface technology and Vessel perfusion system.
Founder and CEO Max Hodak
Last week’s tracker: Brainomix, Trinity and more
Polares Medical raises $50M for heart leaflet replacement system
The financing builds on accelerating clinical momentum, as Polares reports more than 70 patients receiving MRace implants.
DC Global Ventures, Lumination Partners, existing investors and a new strategic investor helped deliver the round. Polares plans to use the funds to advance clinical studies in the U.S., Europe, and Australia.
CEO Jacques Essinger
ANEUVO secures a $22M Series C funding
The financing was led by Catcher Technology, with participation from additional new investors. It provides additional capital to support the company’s next phase of growth.
The investment supports the company’s expansion in approved markets while advancing its long-term commercial and operational infrastructure.
Co-Founder and CEO Yi-Kai Lo
Minnesota Medical Technologies secures $20M in a Series A
The company will use the new capital to fuel the commercial launch of its lead fecal incontinence product in the US market and scale operations to meet growing demand.
The new capital through a Series A preferred equity financing was co-led by HM Venture Partners and Southeast Minnesota Capital Partners.
CEO David Jonas
RAYDIAX secures €7.5M for first-in-human studies and market entry of CT “TACT”
The round includes €5M in venture capital from existing business angels, current investor bmp Ventures with the IBG funds, as well as a new investment from the GETEC Family Office of Dr. Karl Gerhold.
With the newly raised capital, RAYDIAX will implement the first-in-human application of its therapy assistance CT scanner “TACT” to generate early clinical evidence.
Co-Founder and CEO Thomas Hoffmann
Xsensio raises $7M for continuous biosensing tech
The company develops technology for near-real-time continuous biochemical monitoring. It said the new funding enables the acceleration of the development and clinical validation of its Lab-on-Skin wearable biosensing platform.
Venture capital firm WI Harper led the Series A round. Privilège Ventures, the European Innovation Council, and private investors across the United States, Europe and Asia, also participated.
CEO Esmeralda Megally
Worldscape secures a $6M Seed round
This significant capital infusion will enable Worldscape to accelerate the development of its unified open environment.
The funds are earmarked for growth initiatives, including scaling its platform capabilities and expanding its operational reach to meet increasing demand.
CEO Mark Bolz
Cellbox Solutions closes a €3.5M first tranche of Series A financing
The new capital will be used to expand international production and sales activities and to unlock additional application areas, particularly in cell and gene therapy as well as in vitro fertilization (IVF).
The round was led by the digital business angel network Companisto, together with existing investors, including NRW.BANK.
Founder and CEO Kathrin Adlkofer
Noxon closes Seed funding round to advance muscle-computer interface technology
The funding will support the clinical validation and certification of Noxon’s non-invasive Muscle-Computer Interface and preparation for the market launch of its initial therapy modules.
The round was led by High-Tech Gründerfonds (HTGF) and Bayern Kapital, with participation from Auxxo and another institutional investor. The size of the round was not disclosed.
Co-Founder and CEO Maria Neugschwender
